FBXO5, also known as early mitosis Inhibitor 1(EMI1), is involved in cell sensitivity to poly ADP-ribose polymerase (PARP) inhibitors by targeting RAD51 degradation in breast cancer (112). Here, FBXO5 is linked to breast carcinoma.